Searchable abstracts of presentations at key conferences in endocrinology

ea0044p150 | Neuroendocrinology and pituitary | SFEBES2016

Morvan’s syndrome: could insulin like growth factor-1 be a marker?

Edeghere Simon , Browne Duncan , McLean Brendan

Morvan’s syndrome is a rare autoimmune disease characterised by peripheral nerve hyper excitability, CNS symptoms and autonomic dysfunction which can mimic other endocrine presentations with symptoms including hyperhidrosis, weight loss, neuromyotonia and insomnia. Morvan’s is associated with malignancy, in particular thymomas, suggesting paraneoplastic aetiology. This case is the first to associate Morvan’s with renal carcinoma and proposes insulin like growth ...

ea0044ep71 | (1) | SFEBES2016

Morvan’s syndrome: could insulin like growth factor- 1 be a marker?

Edeghere Simon , Browne Duncan , McLean Brendan

Morvan’s syndrome is a rare autoimmune disease characterised by peripheral nerve hyper excitability, central nervous system symptoms and autonomic dysfunction which can mimic other endocrine presentations with symptoms including hyperhidrosis, weight loss, neuromyotonia and insomnia. Morvan’s is associated with malignancy, in particular thymomas, suggesting a paraneoplastic aetiology. This case is the first to associate Morvan’s with renal carcinoma and proposes...

ea0050p250 | Neoplasia, Cancer and Late Effects | SFEBES2017

Immunotherapy and development of endocrine dysfunction: An audit of immune checkpoint inhibitors

Abhi Dhruv , Vennam Sarath , Dugal Tabinda , Edeghere Simon

Introduction: Immune checkpoint inhibitors such as CTLA 4 inhibitors (Ipilimumab) and PD1 inhibitors (Nivolumab/ Pembrolizumab) are being increasingly used for treatment of malignant melanomas and other solid tumours. Despite clinical benefits, they have been known to cause certain Immune related adverse effects (IrAEs) which may be dermatological, gastrointestinal, endocrine, or other immune phenomenon.The endocr...

ea0050p250 | Neoplasia, Cancer and Late Effects | SFEBES2017

Immunotherapy and development of endocrine dysfunction: An audit of immune checkpoint inhibitors

Abhi Dhruv , Vennam Sarath , Dugal Tabinda , Edeghere Simon

Introduction: Immune checkpoint inhibitors such as CTLA 4 inhibitors (Ipilimumab) and PD1 inhibitors (Nivolumab/ Pembrolizumab) are being increasingly used for treatment of malignant melanomas and other solid tumours. Despite clinical benefits, they have been known to cause certain Immune related adverse effects (IrAEs) which may be dermatological, gastrointestinal, endocrine, or other immune phenomenon.The endocr...

ea0086p346 | Neuroendocrinology and Pituitary | SFEBES2022

Immune checkpoint inhibitor related hypothalamus pituitary adrenal axis dysfunction: A retrospective study in Derriford Hospital

Gardner Gemma , Hirwa Kagabo , Pyone Khine May , Patel Nishchil , Edeghere Simon , Flanagan Daniel

Background: Newer biological drugs such as immune checkpoint inhibitors (ICI) have recently revolutionized cancer therapy. However, hypophysitis and adrenalitis are recognized side-effects of these new therapies. Hypothalamus pituitary adrenal (HPA) axis dysfunction is associated with serious morbidity and mortality. This study aimed to monitor whether the ICI related HPA axis dysfunction recovers.Materials and Methods: We have conducted a retrospective ...

ea0059p137 | Neuroendocrinology and pituitary | SFEBES2018

Safety of prescribing for inpatients with cranial diabetes insipidus (CDI): a Southwest Peninsula Audit

Edeghere Simon , Morton Claire , Rogers Sue , Babiker Tarig , Elzain Yamin , Brooke Antonia , Network Peninsula Endocrine

Cranial Diabetes Insipidus (CDI) is associated with significant polyuria and is treated with desmopressin. Inappropriate or missed treatment can result in significant electrolyte imbalance and potential harm. A recent UK survey of Endocrinologists reported 55% had concerns about knowledge in their trust, 39% felt they had observed patients come to harm. Patients not receiving desmopressin have been associated with death, leading to an NHS England (NHSE) safety alert in 2016. W...